Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 28K
2: EX-99.1 Miscellaneous Exhibit HTML 555K
6: R1 Cover Page HTML 45K
8: XML IDEA XML File -- Filing Summary XML 11K
11: XML XBRL Instance -- cah-20240502_htm XML 13K
7: EXCEL IDEA Workbook of Financial Report Info XLSX 8K
4: EX-101.LAB XBRL Labels -- cah-20240502_lab XML 62K
5: EX-101.PRE XBRL Presentations -- cah-20240502_pre XML 33K
3: EX-101.SCH XBRL Schema -- cah-20240502 XSD 10K
9: JSON XBRL Instance as JSON Data -- MetaLinks 12± 17K
10: ZIP XBRL Zipped Folder -- 0000721371-24-000036-xbrl Zip 50K
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
i☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to
Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
iCommon shares (without par value)
iCAH
iNew
York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
i☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. p
Item 2.02: Results of Operations and Financial Condition
On May 2, 2024, Cardinal
Health, Inc. (the "Company") issued a news release announcing its results for the quarter ended March 31, 2024. A copy of the news release is included as Exhibit 99.1 to this report.
Item 7.01: Regulation FD Disclosure
During a webcast scheduled to be held at 8:30 a.m. Eastern time on May 2, 2024, the Company's Chief Executive Officer and Chief Financial Officer will discuss the Company's results for the quarter ended
March 31, 2024, outlook for the fiscal year ending June 30, 2024 and preliminary outlook for the fiscal year ending June 30, 2025. The slide presentation for the webcast will be available on the Investors page at ir.cardinalhealth.com. An audio replay of the webcast also will be available on the Investors page at ir.cardinalhealth.com.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
